This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frédérique Carrie, MD; Pascal Roblot, MD; Serge Bouquet, PhD; Anne Delon, PhD; France Roblot, MD; Bertrand Becq-Giraudon, MD

Arch Intern Med. 1994;154(13):1521-1524.

Abstract
Rifampin is an enzymatic inducer known to increase steroid metabolism. We studied two patients with giant cell arteritis in whom rifampin caused nonresponsiveness to prednisone treatment. A prednisolone pharmacokinetics study was done. When rifampin-prednisone treatment must be used in giant cell arteritis, we propose increasing the prednisone dosage to 2 mg/kg per day.

(Arch Intern Med. 1994;154:1521-1524)

Author Affiliations
From the Internal Medicine Service (Drs Carrie, P. Roblot, F. Roblot, and Becq-Giraudon) and Pharmacokinetics Laboratory (Drs Bouquet and Delon), University Hospital La Milétrie, Poitiers, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia
Wong et al.
The Annals of Pharmacotherapy 2008;42:1737-1748.
ABSTRACT | FULL TEXT  

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Da Silva et al.
Ann Rheum Dis 2006;65:285-293.
ABSTRACT | FULL TEXT  

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med. 2003;167:603-662.
FULL TEXT